LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.

The morbidity associated with metabolic syndrome induced by androgen deprivation therapy (ADT) in prostate cancer (PCa) has not been widely studied. There are no studies comparing surgical and pharmacological castration with regards to their metabolic side effects. The aim of this study was to compare both modalities.

A prospective observational study was conducted in men with PCa and with indications of any ADT. The participants were divided into two groups: (1) bilateral orchiectomy and (2) LHRH analogs. The metabolic profile was assessed before and during the period of ADT. Bioelectrical impedance analysis (BIA) and bone mineral density were measured before and after 6 months of treatment. The data were analyzed using the Chi-squared test, Student's t test, Bonferroni's test, and ANOVA.

We enrolled 102 men for analysis, of whom 46 (54.9 %) had been subjected to bilateral orchiectomy and 56 (54.9 %) had been subjected to treatment with LHRH analogs. The basal metabolic profile, body mass index, and BIA were similar between the two groups. The oncologic control (PSA and testosterone) was also similar in both groups. In the intergroup comparison, insulin resistance (p = 0.044) and hemoglobin (p = 0.001) were worse in the group that used LHRH analogs, which was mainly diabetic patients (p = 0.007).

This study showed that LHRH analogs had worse effects relative to insulin resistance, mainly in diabetic patients, and induced more anemia and bone demineralization compared to surgical castration. Further prospective, randomized, and comparative studies are needed for metabolic syndrome in ADT modalities.

World journal of urology. 2016 Apr 21 [Epub ahead of print]

Andreza Vargas, Roberto Dias Machado, Daniel Ianni Filho, Carlos Eduardo Paiva, Rodolfo Borges Dos Reis, Marcos Tobias-Machado, Eliney Ferreira Faria

Department of Urology, Barretos Cancer Hospital, Antenor Duarte Vilela St, 1331, Bairro Dr Paulo Prata, Barretos, CEP: 14.784.400, Brazil., Department of Urology, Barretos Cancer Hospital, Antenor Duarte Vilela St, 1331, Bairro Dr Paulo Prata, Barretos, CEP: 14.784.400, Brazil., Department of Urology, Barretos Cancer Hospital, Antenor Duarte Vilela St, 1331, Bairro Dr Paulo Prata, Barretos, CEP: 14.784.400, Brazil., Department of Urology, Barretos Cancer Hospital, Antenor Duarte Vilela St, 1331, Bairro Dr Paulo Prata, Barretos, CEP: 14.784.400, Brazil., Department of Urology, University of São Paulo, Av. Bandeirantes, 3.900 Monte Alegre, Ribeirão Prêto, SP, CEP: 14040-900, Brazil., Department of Urology, ABC Medical School, Av. Príncipe de Gales, 821 - Príncipe de Gales, Santo André, SP, CEP: 09060-650, Brazil., Department of Urology, Barretos Cancer Hospital, Antenor Duarte Vilela St, 1331, Bairro Dr Paulo Prata, Barretos, CEP: 14.784.400, Brazil. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe